Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Foghorn Therapeutics (Nasdaq: FHTX) announced management will participate in three investor conferences in November 2025: Guggenheim Second Annual Healthcare Innovation Conference, Stifel 2025 Healthcare Conference, and Jefferies 2025 London Healthcare Conference.
Fireside chat dates and times: Guggenheim Nov 10, 2025 at 11:00 AM ET; Stifel Nov 13, 2025 at 4:00 PM ET; Jefferies London Nov 19, 2025 at 10:30 AM GMT. Presenter: Adrian Gottschalk, President and CEO. Webcasts will be available in Investors > Events & Presentations on the company site for 90 days.
Details
News Market Reaction – FHTX
On Nov 3, the day this news came out, FHTX closed 4.54% below the previous close.
Data tracked by StockTitan Argus for the Nov 3 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in the Guggenheim Second Annual Healthcare Innovation Conference, Stifel 2025 Healthcare Conference, and Jefferies 2025 London Healthcare Conference. With an initial focus in oncology, Foghorn’s Gene Traffic Control® platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.
Guggenheim Second Annual Healthcare Innovation Conference
- Fireside Chat: Monday, November 10, 2025, at 11:00 a.m. ET
- Presenter: Adrian Gottschalk, President and Chief Executive Officer
- Management will also participate in one-on-one meetings
Stifel 2025 Healthcare Conference
- Presentation: Thursday, November 13, 2025, at 4:00 p.m. ET
- Presenter: Adrian Gottschalk, President and Chief Executive Officer
- Management will also participate in one-on-one meetings
Jefferies 2025 London Healthcare Conference
- Fireside Chat: Wednesday, November 19, 2025, at 10:30 a.m. GMT
- Presenter: Adrian Gottschalk, President and Chief Executive Officer
- Management will also participate in one-on-one meetings
A webcast of the available presentations can be accessed under “Events & Presentations” in the Investors section of the Company’s website, www.foghorntx.com, and will be available for 90 days.
About Foghorn Therapeutics
Foghorn® Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control® platform, Foghorn is systematically studying, identifying, and validating potential drug targets within the chromatin regulatory system. The Company is developing multiple product candidates in oncology. Visit our website at www.foghorntx.com for more information on the Company, and follow us on X and LinkedIn.
Contact:
Karin Hellsvik, Foghorn Therapeutics Inc.
khellsvik@foghorntx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.